Ultromics recently joined as a full partner with the Accelerating Medicines Partnership Heart Failure initiative, designed to develop new diagnostic tools for heart failure.
The initiative also includes the U.S. National Institutes of Health and the National Heart Lung and Blood Institute, managed by the Foundation for the National Institutes of Health. The five-year, $37 million collaboration aims to investigate the syndrome of heart failure with preserved ejection fraction (HFpEF).
Ultromics' artificial intelligence tools will be utilized in the research. The company's HFpEF diagnostic algorithm was recently granted breakthrough status from the U.S. Food and Drug Administration for the first HFpEF diagnostic algorithm. Ultromics said this algorithm can detect HFpEF by analyzing the motion of the heart chamber walls from a single echocardiography image.
